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R. Rodney Howell, MD.t
DR. HOWELL: Max, thank you, very much. It's my pleasure to
be here today to talk about newborn screening with this distinguished
group of LC researchers and clinicians.
This afternoon, what I'm going to do is to spend the time I have
talking with you about some systems that are in place and that are
being put in place nationally, to decide, whether or not, indeed, condi-
tions are treatable in the newborn screening panel. And I'll go through
some of the rationale behind that as we proceed.
These first comments are well known to all of you. Newborn
screening has been around for a long time. I think, fundamentally,
however, once a serious but apparently treatable condition has been
identified, it has been felt that controlled studies in those conditions
would be not ethically sound. And this has resulted in the fact that
they are extraordinarily meager studies in outcomes and, particularly,
in peer-reviewed journals. The amount of information on these rare
conditions has continued to be meager. And the result is that in very
few of the conditions do we have, really, what we would consider
perfect information about the effective treatment in the long-term out-
comes.
This has been discussed extensively and this panel is very much
aware about the American College of Medical Genetics panel that
came up with the recommended uniform panel. This has been widely
discussed. This group, as you know, recommended a core panel of 29
conditions. The secondary targets were a number of 25. We could
spend a month talking about this and I'll be glad to discuss it with
anybody in private. There are a few conditions that are excluded and
a considerable number of conditions that were not on the panel be-
cause there was no test available.
I might point out this report has not only been groundbreaking as
far as changing the practice of newborn screening in the United States,
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it has, arguably, been one of the most discussed documents, of, cer-
tainly, my lifetime. And many folks in this room, as I sit around look-
ing, have written highly critical documents about this. I can see two
without changing my eye. What I might point out is that there were
29 put on primary conditions and 25 secondary targets. But I will
include one article from a scientific journal that is Nature Genetics
and I have quoted this in view of the company present today. Nature
Genetics said in 2007, "perhaps we can learn from one of the most
impressive recent exercises in evidence-based medicine, namely the
American College of Medical Genetics Systematic Prioritization of
Genes for Newborn Screening." I will not further comment about
that.
Now, what are some of the challenges that we have to deal with in
the area of newborn screening? Number one, there are enormous ex-
pansions of potential targets and that's just been emphasized in Don's
recent presentation. Poor understanding of the clinical significance,
scalability, affordability, invariability of complexes of policy, but we
come down to the bottom line again, of striking lack of published
peer-reviewed articles. And I might point out there were more than
100 people that worked on the ACMG report that you've seen here for
a couple of years. And it was the people whose careers have been
devoted to this, but families were involved. There were legal people,
ethicists, et cetera. The basic fact was is that there was not a lot of
concrete, long-term information about many of these conditions and
everyone was very much aware of that.
What are some of things that are going on that I think will impact
our information about the conditions that are on the panel? I'd like to
discuss, briefly, the recent collaborative screening and genetics col-
laborative groups around the country. Many of you are very familiar
with this in that the HRSA has established this group of folks, whose
goals were to address mal-distribution of genetic resources, promote
genetics, promote translation of genetic medicine in the public health
and healthcare services, cooperate in studies to establish best labora-
tory practices and the appropriate cut-off phase. I'm going to spend a
good bit if time with that in the later panel. But also to work with
national groups to effect, to evaluate treatment outcomes and long-
term follow-up. There are seven of these regional collaborative
groups and one national coordinating center that is operated with
HRSA.
This is the map for those of you - many of you work within these
and you're very familiar with these, but basically, you have the United
States, divided up into seven regions. The great value of this, aside
from the sharing of information and so forth, is that these groups are
closely involved with the state health departments in all of the regions
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and they have contact with the folks who are collecting the patients
and the information and so they provide an extraordinarily good op-
portunity to do a large number of things and there are many things
going on.
The groups are encouraged to establish cooperative programs.
Region 4 is one region that is currently working very, very hard in an
international collaboration. It has actually, expanded beyond the
seven regions and now has people from all over the world to look at
cut-offs and false positives. And the other regions around the country
are developing individual projects. But the reason I go into this sys-
tem is that the next part of my discussion is going to be discussing a
recently announced NIH program that will be dealing and will be built
on top of the original collaborative programs. I might point out that
Jeff Botkin today asked about the action sheets that are handed out
through the regional collaborative networks to address one of the key
problems with newborn screening. As this group is intimately aware,
the conditions, individually, are rare, and it would be unrealistic to
expect any practitioner to be aware of all of these conditions. The
typical situation that happens is that on Friday afternoon - it'd be a
day like this - about this time of day on a rainy Friday afternoon, you
get a call in your office that you have a child that has just been
screened positive in the state health department with the condition that
you, literally, have never heard of. That is the paradigm that we deal
with.
I might point out, these ACT sheets are designed to be available
online and they, actually, are online and they have been developed for
all the core and secondary targets. They are really designed to pro-
vide immediate point of learning, education and so forth. And they
also are currently included in the American Academy of Pediatrics'
plan at the newborn clinical report in their task force.
Let me just show you one of these. Many of you are familiar with
these, but this happens to be the one for thyroid disorders. And it,
basically, provides a differential diagnosis. It tells you exactly what
to do, immediately. It has some comments about the diagnostic
evaluation and it then has some additional information you can click
on and go there. We have not yet talked about the genetic home ref-
erence, and I am not going to talk about that today, but the National
Library of Medicine, working with the parts of the NIH, has on its
Genetic Home Reference site all of the conditions that are included in
the panel and it's done for parents. And so, it is a very nice source for,
really, highly vetted information. I might point out that certain states
have their own ACT sheets that are customized for their specific pro-
gram. But it is also intended that these national Act sheets will also
be customized for the local site.
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The thing I would like to talk about next is the fact that NICHD
has recognized that there is a very meager amount of information
about these conditions and so, fundamentally, one that they have
funded a variety of programs that I have listed here about innovative
technologies and strategies. One of the things that they are currently
involved in is to set up a NICHD newborn screening translational
research network. There is some background information about the
need, et cetera and NICHD proposes to establish this network, and it
is far beyond a proposal at this time in that the contract for the coordi-
nating center of this network will be awarded in the current federal
fiscal year. So, it will be awarded before October of this year. These
are the kinds of things that this network is expected to do. Number
one, it is planned to develop a virtual repository for residual dried
blood spots, as appropriately stored by the states, that they would de-
velop and oversee laboratory and practice standard guidelines and
work with the laboratories for the clinical diagnosis included in the
panel so there would be specific discussions about diagnostic confir-
mation; that they would develop policies and recommendations about
informed consent that might be appropriate for newborn screening.
We are all aware of the fact that informed consent documents must be
developed at the institutional level, but we are also aware of the fact
that national collaborative groups such as the Children's Oncology
group make a great deal of progress by having a nationally vetted in-
formed consent that applies - that then can be worked on at the insti-
tution locally.
Fundamentally, the long-term plan is that this network would pro-
vide a mechanism by which research can be initiated and there can be
long-term follow-up of patients with rare conditions, et cetera, as a
research effort. This is a five year proposal for the coordinating cen-
ter and, as times goes along, it will have additional activities to coor-
dinate between other state and federal estimates and develop standard
protocols and research. It will also be working on a data-sharing pol-
icy so that there can be nationally acquired data on the various and
sundry children who are being diagnosed and how they will be fol-
lowed-up in some of the research protocols. This is, in general, what
it would look like: the translation research coordinating center in the
center, but working with various and sundry grants, and coordinating
many activities. There will be a steering committee and this will be
closely tied to the states' newborn screening programs.
Let me comment just briefly in my final remarks about the advi-
sory committee on heritable disorders and genetic diseases in new-
bors and children and the law that was just signed last week has
shortened the name, mercifully. That committee has been just re-
newed for another five years. Fundamentally, this is a broadly based
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committee that provides recommendations to the Secretary of Health
and Human Services about the appropriate application of universal
screening, newborn tests, technologies, policies, guidelines and pro-
grams. Now, many of you are aware of this committee and many of
you have been involved with the committee, but it has medical, tech-
nical and scientific people. It has a broad group of public members
and representatives from the federal agencies, such as the March of
Dimes and other professional groups who have relevance to newborn
screening.
The committee is currently looking at new nominations for new-
born screening and the nomination process, as outlined here, is to be a
very broad process where anybody can make nominations. It would
be streamlined; it would be transparent and there are consistent crite-
ria. And the main areas for consideration by the group will be the
condition, the test and the treatment. This is the form that is on the
web site of HRSA and it is a very simple form, I might point out. It
takes a lot of time to fill it out properly, but basically, there is infor-
mation about the condition, the incidence, the timing of onset and
severity, the test, such as the screening test to be used and the modal-
ity of screening, validity, confirmation and the risk of false positive
and carrier detections and things of that nature, the treatment, modal-
ity, urgency, efficacy, availability, risk and then the references.
This nomination then comes to the committee. But one thing that
recently has changed, and that we think that will be a very big issue, is
that once this report comes to the advisory committee, if the advisory
committee thinks that yes, this looks like a perfectly reasonable pro-
posal, it then will go to a totally external evidence-based committee.
And that committee is operating under a contract with HRSA, but it is
totally independent from the advisory committee and it is headed by a
group of distinguished folks at Harvard who are involved in evidence-
basis research and is headed by Dr. Jim Perrin. And that group will
do a formal review of the evidence about these rare conditions. And I
might point out that formal evidence review in these rare conditions
just has not been done before and they have really spent a lot of time
thinking about it. They have identified some issues that we are aware
of, the lack of randomized trials, they are rare. There is limited in-
formation on the cost. They are concerned about access to the evi-
dence; the published evidence is meager, as you know. There are
unpublished results that they will look at. They are going to try to get
as much as possible FDA data, such as when you introduce a new
therapy, such as Myozyme, where you have an approved drug; the
FDA will have those data. And they are going to use proprietary data,
when possible. They will review the thing just to be sure that the
form is filled out and so forth.
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And I might point out, as of this moment, the Maternal and Child
Health Bureau has already received five nominations for conditions,
as I have shown here. Two have been seen sufficiently by the com-
mittee to send to the evidence group and so forth. And those two that
have been seen by the committee and sent out for evidence review, is
Pompe disease and Severe Combined Immune Deficiency (SCID).
Those are the two conditions that have gotten to that point.
The evidence review is going to publish all of their material, but
they will have a clear conflict of interest policy. That is a very inter-
esting issue, because most of the people that recommend conditions of
this nature are heavily conflicted because they have either been in-
volved in research or they have families with the condition. And it is
a very small community. They recognize that; they want to have that
clearly stated.
Let me zip through some of the things. They are going to review
the natural history, including variations in phenotype, the prevalence,
impact and severity, methods of screening and diagnosis and things of
that nature; the feasibility and acceptability of screening. They are
going to look at the benefits of treatment, screening positive individu-
als otherwise diagnosed persons. Harms or risks involved in the
screening, diagnosis and treatment and the cost.
They are publishing their search methods, such as the time frame
and the search engines that they have used. They are going to use
peer-reviewed English literature, English only. Gray literature, they
are going to review. They are going to exclude case reports. I think
that this will be an interesting problem, because so much of the mate-
rial in here tends to be individual or small numbers of the cases. They
are going to review consensus statements, but not for abstraction.
They are going to, once they have finished with all the data abstrac-
tion and quality assessments and so forth, and analyze the raw data
that they have. They are then going to have focus groups that will
discuss their findings and they will make the input public, which
would include families and investigators.
And severity estimates are particularly important. For example,
for those of us who have been taking care of your children for a long
time, we tend to think that, well, you know that, the diet, the PKU is a
very straight forward treatment. Families do not think so. It is a big
deal; it is very complicated. And so severity will clearly have a very
different view depending on whether or you're living with it or at a
distance.
Finally, once this evidence review, it will come back to the advi-
sory committee. All the decisions will be made by the advisory com-
mittee and some of the possible recommendations from the advisory
committee will be that this is recommended for universal screening,
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that there should be some targeted screening done, or some pilot stud-
ies done. They will identify studies that will be done and, hopefully,
that will feed back to the NIH who will say, if there are studies that
need to be done, these should be proposals that are sent out as RFAs
and so forth.
No recommendation is listed here as an outcome, which I think is
an unfortunate turn, because I think if you do not make any recom-
mendation that tends to be a recommendation of sorts. And you can
recommend against newborn screening.
But anyway, I think that one of the - I will close with this. That
is, I will comment briefly about public law, 110-204, that was signed
on April 24th by President Bush and the working document was the
Newborn Screening Saves Lives Act. That legislation authorizes 58
and a half million dollars to improve, expand, coordinate and evaluate
federal research, education, programmatic activities. It is intended to
help the state and local health agencies to provide screening, counsel-
ing, healthcare services, state laboratories, parents, families, and fund
new technologies and follow-up treatment. So we will be very inter-
ested to see what happens with that.
I think that it was widely felt that there was not a chance that
would get through the Senate. It was further confirmed that there was
not a chance that it would get through the House. And thirdly, it was
felt there was not a chance the President would sign it. And all three
of those happened. And I might point out, almost exclusively, be-
cause of very active parent and advocate procedures. Now the same
people that told me all those three things, there is not a chance that
any money will be appropriated, but we will have to see.
Thank you very much. (Applause).
(Presentation concluded.)

